Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 294

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 294
---
 FYARRO and other commercially important technologies, inventions, and know-how related to our
business, defend and enforce our intellectual property rights, in particular, our patent rights, preserve the confidentiality of our trade secrets, and operate without infringing valid and enforceable intellectual property rights of others.

The patent positions for biotechnology and pharmaceutical companies like us are generally uncertain and can involve complex legal, scientific, and factual
issues. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. In
addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. As a result, we cannot guarantee that FYARRO will be protected or
remain protectable by enforceable patents. Moreover, any patents that we hold may be challenged, circumvented, or invalidated by third parties. For more information regarding the risks related to our intellectual property please see “Risk
Factors- Risks Related to Our Intellectual Property”.

We own or exclusively license fifteen (15) issued patents in the United States as well as
issued patents in other countries. With respect to our licensed patents, we have exclusive, sublicensable rights to certain patents and patent applications relating to FYARRO under our license agreement with BMS. As of December 31, 2024, we
licensed seven (7) issued U.S. patents with composition of matter and method of use claims covering FYARRO. The first issued U.S. patent is set to expire in 2029, subject to patent term extension, and the other four are expected to expire in
2030, 2036, 2036, 2036, 2036 and 2040, respectively. In addition, we licensed related patents and patent applications in Europe, Australia, North America, South America, and Asia that are expected to expire between 2026 and 2040. We also own or
licensed many pending U.S. applications and related pending applications in Europe, Australia, North America, South America, Africa, and Asia.

The term
of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a
non-provisional patent application.

In the United States, the term of a patent covering an FDA